Recruiting for Molto Study

The Molto study has opened at the Christie Hospital, Manchester. The trial is recruiting women with a germline BRCA1/2 mutation and recurrent, platinum-sensitive, high-grade serous or endometrioid ovarian cancer.

 

The trial offers patients the opportunity to receive two courses of Olaparib following a response to platinum based therapy (carboplatin or cisplatin). Olaparib is an inhibitor of an enzyme called poly(adp) ribose polymerase (parp) and recently published phase 2/3 clinical trials have shown that it delays recurrence in women with high-grade serous ovarian carcinoma and a germline BRCA1/2 mutation. Olaparib has been licensed as a maintenance treatment in women with a BRCA1/2 mutation and high-grade serous ovarian cancer after 2 lines of platinum based therapy and is available through NHS funding after 3 lines of platinum based therapy. 

 

Molto is a phase 2 non-commercial trial, assessing whether a second course of Olaparib maintenance therapy is safe and effective after control of the ovarian cancer with further chemotherapy. There are two points of entry for patients with a BRCA mutation: the first is where patients have not received Olaparib following the most recent chemotherapy and the second entry point is when patients have just completed a first course of Olaparib and now require further chemotherapy to control their ovarian cancer. As part of the Molto study the investigators are asking all participants to undergo a biopsy prior to starting either line of chemotherapy to better understand the biology of ovarian cancer.

 

If you believe you have a patient to recommened or wish to find out more information about this trail, please contact Professor Gordon Jayson at the Christie Hospital, Manchester.

 

If you have a mutation in BRCA and are interested in taking part in the Molto studyplease ask your doctor/oncologist to contact Professor Gordon Jayson at the Christie Hospital, Manchester.